Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed invasive breast cancer meeting the
following criteria:

- Early-stage disease

- No stage IV disease

- More than one synchronous primary breast tumor

- Lymph node positive OR high-risk lymph node negative

- Candidate for treatment with anthracycline- and taxane-based chemotherapy in the
adjuvant setting

- Must begin therapy within 84 days after the final required surgical procedure

- HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0,
1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified

- No CNS disease (e.g., primary brain tumor or brain metastasis)

- Hormone receptor status known

PATIENT CHARACTERISTICS:

- Male or female

- Pre- or post-menopausal

- ECOG performance status 0-1

- Absolute neutrophil count ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3

- Bilirubin normal

- AST or ALT ≤ 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Urine protein:creatinine ratio ≤ 1.0

- PT and PTT normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after
completion of study therapy

- LVEF normal by MUGA scan at baseline

- No significant bleeding within the past 6 months

- No uncontrolled underlying bleeding diathesis

- No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would
preclude study therapy, including any of the following conditions:

- Blood pressure > 150/100 mm Hg

- Unstable angina

- New York Heart Association class II -IV congestive heart failure

- Myocardial infarction or stroke within the past 12 months

- Clinically significant peripheral vascular disease

- No seizures not controlled with standard medical therapy

- No history of stroke

- No known allergy or hypersensitivity to study drugs (prior hypersensitivity to
paclitaxel allowed)

- No significant traumatic injury within the past 28 days

- No serious nonhealing wound, ulcer, or bone fracture

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 6 months

- No active gastroduodenal ulcer

- No uncontrolled intercurrent illness, including psychiatric illness or social
situation that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Prior therapy for an ipsilateral or contralateral breast cancer primary allowed
provided the following criteria are met:

- No prior anthracycline therapy

- Prior hormonal therapy for this previous breast cancer is allowed, but must be
stopped during study therapy

- At least 1 year since prior taxane therapy

- More than 28 days since prior and no concurrent major surgery or open biopsy

- Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed
during the course of the study (bevacizumab will be held during that time as per
protocol guidelines)

- More than 7 days since prior minor surgery, including fine-needle aspiration or core
biopsy

- At least 24 hours since prior indwelling catheter placement

- No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668,
vandetanib, vatalanib, AEE788, or IMC-1CII)

- No concurrent full-dose anticoagulation therapy

- No concurrent hormonal therapy as chemoprevention

- Concurrent participation in adjuvant hormone therapy or correlative or companion
(e.g., bisphosphonate clinic) studies allowed

- No other concurrent anticancer therapy